NANTES, FRANCE and MARSEILLE, FRANCE--(MARKET WIRE)--Sep 11, 2007 -- VIVALIS (Euronext : VLS) and INNATE PHARMA (Euronext : IPH) announce today having launched a scientific collaboration to evaluate VIVALIS EBx® cell lines, derived from avian embryonic stem cells, for the production of monoclonal antibodies. The first concrete results prove once again the efficacy of EBx® technological platform developed by VIVALIS compared to CHO cells which are currently the reference for monoclonal antibody production.
